Work

Controversy Surrounding ROCKET-AF: A Call for Transparency, But Should We Be Changing Practice?

Year: 2016

Type: article

Abstract: Prior to the emergence of novel oral anticoagulants (NOACS), nearly all patients were prescribed vitamin K antagonists for thromboembolic prophylaxis in non-valvular atrial fibrillation (AF). Rivaroxaban (Xarelto, Bayer/Johnson & Johnson), an oral factor Xa inhibitor, is now one of the most frequently prescribed NOACs used for this indication.1,2

Source: Arrhythmia & Electrophysiology Review

DOI: 10.15420/aer.2016.24.2

Authors: Jason D Matos, Peter J Zimetbaum

Institutions: Beth Israel Deaconess Medical Center, Harvard University

Language: English

Topic: Atrial Fibrillation Management and Outcomes

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $2,146